A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

NCT07326709 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

770

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntington Disease

Interventions

DRUG: Votoplam (blinded)
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals